Drugs /

bavituximab

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
bavituximab
NCI Definition [1]:
A chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Bavituximab binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels.

Clinical Trials

View Clinical Trials for bavituximab

Bavituximab has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating bavituximab, 3 are phase 2 (3 open) and 1 is phase 2/phase 3 (0 open).

Deficient DNA Mismatch Repair (dMMR), ERBB2 Amplification, and HER2 Overexpression are the most frequent biomarker inclusion criteria for bavituximab clinical trials.

Adenocarcinoma of the gastroesophageal junction, breast carcinoma, and gastric adenocarcinoma are the most common diseases being investigated in bavituximab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Bavituximab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Bavituximab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating bavituximab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
tarvacin, bavituximab, chimeric anti-phosphotidylserine monoclonal antibody
Drug Categories [2]:
Immunotherapies
NCIT ID [1]:
C49088

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.